Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.2.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 379,157 $ 329,086 $ 767,645 $ 631,163
OPERATING EXPENSE:        
Medical expense 365,171 302,271 747,228 587,841
Premium deficiency reserve (3,397) (2,012) (2,397) 3,128
Corporate, general and administrative expense 26,610 27,223 54,011 64,866
Sales and marketing expense 414 857 736 1,858
Depreciation and amortization 21,693 21,780 43,232 43,320
TOTAL OPERATING EXPENSE 410,491 350,119 842,810 701,013
OPERATING LOSS (31,334) (21,033) (75,165) (69,850)
OTHER INCOME (EXPENSE):        
Interest expense, net (5,436) (3,851) (9,692) (7,937)
Mark-to-market of stock warrants 8,673 (1,731) 8,889 (1,082)
Other 291 (741) 628 (645)
TOTAL OTHER EXPENSE 3,528 (6,323) (175) (9,664)
LOSS BEFORE INCOME TAXES (27,806) (27,356) (75,340) (79,514)
PROVISION FOR INCOME TAXES (968) (226) (3,040) (516)
NET LOSS (28,774) (27,582) (78,380) (80,030)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST (16,754) (17,766) (47,660) (61,015)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST $ (12,020) $ (9,816) $ (30,720) $ (19,015)
NET LOSS PER SHARE (Note 9):        
Basic (in dollars per share) $ (0.09) $ (0.09) $ (0.24) $ (0.25)
Diluted (in dollars per share) $ (0.15) $ (0.09) $ (0.30) $ (0.29)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):        
Basic (in shares) 136,601 107,454 127,806 74,699
Diluted (in shares) 141,083 107,454 130,047 276,028
Capitated Revenue [Member]        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 374,306 $ 325,616 $ 758,440 $ 624,320
Other patient service revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 4,851 $ 3,470 $ 9,205 $ 6,843